A Case of Chronic Granulomatous Disease in which the Patient Survived a Recurrence of Suspected Aspergillus Brain Abscess

Narita, Mitsuo

doi:10.11150/kansenshogakuzasshi1970.73.783

Cited by 3 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overwhelming majority of such reports involve Aspergillus CNS infections with and without abscesses. [29][30][31][32][33][34][35][36][37][38] Several cases have described CNS infections complicated by obstructive hydrocephalus in CGD pediatric patients, 33,[39][40][41]45 but we found only one other report in the literature of obstructive hydrocephalus in an adult CGD patient. 16 Other previously described cases of CNS infection in CGD patients involve tuberculosis, 41 Salmonella, 42,43 Phaeoacremonium parasiticum, 44 Alternaria infectoria, 45 and Scedosporium prolificans.…”

Section: Discussioncontrasting

confidence: 44%

A Systematic Review of Combination Therapies for Smoking Cessation

Nhan¹,

Windle²,

Eisenberg³

et al. 2015

Can Journ Gen Int Med

View full text Add to dashboard Cite

Introduction: The use of pharmacological and behavioural therapies has been shown to help smokers quit. However, the efficacy of combining smoking cessation therapies remains poorly understood. We conducteda systematic review of randomized controlled trials (RCTs) with factorial designs to assess the efficacy of combination smoking cessation therapies.Methods: We performed a systematic search of the Cochrane Library, EMBASE, PsycINFO, and PubMed databases for RCTs of combination therapies for smoking cessation. We included RCTs with factorial designs,reporting biochemically validated point prevalence or continuous abstinence outcomes at 6 or 12 months.Combination therapies were either two pharmacotherapies or apharmacotherapy with behavioural therapy.Pharmacotherapies included nicotine replacement therapies (NRTs), bupropion, and varenicline. Behavioural therapies included counselling and minimal intervention.Results: A total of 11 RCTs met our inclusion criteria: 4 combinations of pharmacotherapies and 7 combinations of a pharmacotherapy with behavioural intervention. Combinations were two NRTs (2 RCTs), bupropion with NRT (3 RCTs), bupropion with behavioural intervention (4 RCTs), and NRT with behavioural intervention (3 RCTs). No identified trials combined varenicline with other included pharmacotherapies. Combining pharmacotherapies did not increase smoking abstinence at 6 or 12 months, compared with pharmacologicalmonotherapies. Evidence suggests a modest yet inconsistent benefit from combining pharmacotherapy withbehavioural therapy.Conclusion: Evidence from RCTs with factorial designs does not conclusively show combination smoking cessation therapies to be superior to monotherapies. Pharmacotherapies could be prescribed without behavioural therapy, with minimal loss of treatment efficacy.Key words: Smoking cessation, combination therapy, systematic review

show abstract

Section: Discussioncontrasting

confidence: 44%

A Systematic Review of Combination Therapies for Smoking Cessation

Nhan¹,

Windle²,

Eisenberg³

et al. 2015

Can Journ Gen Int Med

View full text Add to dashboard Cite

show abstract

“…Brain abscess has been well described in patients with CGD. Various pathogens have been associated with brain abscess development including Scedosporium prolificans [81], Alternaria infectoria [82], Salmonella enterica subspecies houtenae [83], and Aspergillus [84,85]. Other complications associated with CGD include white matter disease [86], CNS granulomatous disease [87] and leptomeningeal, and focal brain infiltration by pigmented, lipid-laden macrophages [88].…”

Section: Clinical Aspectsmentioning

confidence: 99%

Chronic granulomatous disease: a review of the infectious and inflammatory complications

et al. 2011

View full text Add to dashboard Cite

Chronic Granulomatous Disease is the most commonly encountered immunodeficiency involving the phagocyte, and is characterized by repeated infections with bacterial and fungal pathogens, as well as the formation of granulomas in tissue. The disease is the result of a disorder of the NADPH oxidase system, culminating in an inability of the phagocyte to generate superoxide, leading to the defective killing of pathogenic organisms. This can lead to infections with Staphylococcus aureus, Psedomonas species, Nocardia species, and fungi (such as Aspergillus species and Candida albicans). Involvement of vital or large organs can contribute to morbidity and/or mortality in the affected patients. Major advances have occurred in the diagnosis and treatment of this disease, with the potential for gene therapy or stem cell transplantation looming on the horizon.

show abstract

A Streptococcus Intermedius Brain Abscess Causing Obstructive Hydrocephalus and Meningoventriculitis in an Adult Patient with Chronic Granulomatous Disease

Kamar

Dhingra²

2015

CJGIM

View full text Add to dashboard Cite

A Case of Chronic Granulomatous Disease in which the Patient Survived a Recurrence of Suspected Aspergillus Brain Abscess

Cited by 3 publications

References 7 publications

A Systematic Review of Combination Therapies for Smoking Cessation

A Systematic Review of Combination Therapies for Smoking Cessation

Chronic granulomatous disease: a review of the infectious and inflammatory complications

A Streptococcus Intermedius Brain Abscess Causing Obstructive Hydrocephalus and Meningoventriculitis in an Adult Patient with Chronic Granulomatous Disease

Contact Info

Product

Resources

About